Literature DB >> 15349694

[Cutaneous lymphoma].

M Beyeler1, G Burg, R Dummer.   

Abstract

Cutaneous lymphomas are uncommon. They must be distinguished from secondary skin manifestations of primary nodal lymphomas. Primary cutaneous lymphomas are divided into B-cell- and T-cell cutaneous lymphoma and commonly have good prognosis. Therapy is based on the stage of the disease. Since cure is not possible, the aim of treatment is to control the disease and reduce symptoms. A variety of new and promising therapeutic modalities have been introduced in recent years.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349694     DOI: 10.1007/s00105-004-0816-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  12 in total

Review 1.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.

Authors:  Eric C Vonderheid; Maria Grazia Bernengo; Günter Burg; Madeleine Duvic; Peter Heald; Liliane Laroche; Elise Olsen; Mark Pittelkow; Robin Russell-Jones; Masahiro Takigawa; Rein Willemze
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

2.  Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up.

Authors:  U Wollina; T Graefe; M Kaatz
Journal:  Ann N Y Acad Sci       Date:  2001-09       Impact factor: 5.691

Review 3.  [Primary cutaneous B-cell lymphomas].

Authors:  Helmut Kerl; Lorenzo Cerroni; Regina Fink-Puches; Ingrid H Wolf
Journal:  J Dtsch Dermatol Ges       Date:  2004-07       Impact factor: 5.584

Review 4.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

Authors:  R Willemze; H Kerl; W Sterry; E Berti; L Cerroni; S Chimenti; J L Diaz-Peréz; M L Geerts; M Goos; R Knobler; E Ralfkiaer; M Santucci; N Smith; J Wechsler; W A van Vloten; C J Meijer
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

5.  Approach to lymphoproliferative infiltrates of the skin. The difficult lesions.

Authors:  W Kempf; R Dummer; G Burg
Journal:  Am J Clin Pathol       Date:  1999-01       Impact factor: 2.493

6.  Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study.

Authors:  F Grange; M W Bekkenk; J Wechsler; C J Meijer; L Cerroni; M Bernengo; J Bosq; G Hedelin; R Fink Puches; W A van Vloten; P Joly; M Bagot; R Willemze
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.

Authors:  M W Bekkenk; F A Geelen; P C van Voorst Vader; F Heule; M L Geerts; W A van Vloten; C J Meijer; R Willemze
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

8.  A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.

Authors:  F J Kaye; P A Bunn; S M Steinberg; J L Stocker; D C Ihde; A B Fischmann; E J Glatstein; G P Schechter; R M Phelps; F M Foss
Journal:  N Engl J Med       Date:  1989-12-28       Impact factor: 91.245

9.  CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Français d'Etude des Lymphomes Cutanés (GFELC).

Authors:  T Petrella; S Dalac; M Maynadié; F Mugneret; E Thomine; P Courville; P Joly; B Lenormand; L Arnould; J Wechsler; M Bagot; C Rieux; J Bosq; M F Avril; A Bernheim; T Molina; A Devidas; M H Delfau-Larue; P Gaulard; D Lambert
Journal:  Am J Surg Pathol       Date:  1999-02       Impact factor: 6.394

Review 10.  Pathology of cutaneous T-cell lymphoma.

Authors:  G Burg; R Dummer; S Dommann; F Nestle; B Nickoloff
Journal:  Hematol Oncol Clin North Am       Date:  1995-10       Impact factor: 3.722

View more
  1 in total

1.  [A progressive ulcerative neck mass on the left infraauricular area].

Authors:  M A Broglie; M Tinguely; F Stenner; S J Stöckli
Journal:  HNO       Date:  2008-10       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.